@article{APM10782,
author = {Kwok-Ying Chan and Richard Shek-Kwan Chang and Vikki Wai-Kee Lau and Man-Lui Chan and Theresa Lai},
title = {Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine},
journal = {Annals of Palliative Medicine},
volume = {5},
number = {4},
year = {2016},
keywords = {},
abstract = {Lambert-Eaton myasthenic syndrome (LEMS) is an uncommon autoimmune idiopathic or paraneoplastic syndrome producing antibodies against voltage presynaptic calcium channels. According to previous studies, many patients with LEMS experience remission in both the clinical symptoms of muscle weakness and the electrophysiologic abnormalities after successful treatment of lung SCC. However, some patients might not respond to conventional therapy and eventually require palliative care. Hereby, we reported a LEMS patient with advanced lung malignancy was referred for palliative care. He was benefited from multidisciplinary approach even with limited survival. In this case, use of 3,4-diaminopyridine (3,4-DAP) had other roles apart from symptomatic treatment.},
issn = {2224-5839}, url = {https://apm.amegroups.org/article/view/10782}
}